Full Press Release Details
Novavax Appoints Biotechnology Veteran
to Board of Directors
Md., June 16, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation
vaccines for serious infectious diseases, today announced that it has appointed David Mott as an independent director to its Board
of Directors. Mr. Mott brings more than three decades of global management, board and investment experience across numerous private
and public biopharmaceutical companies. Prior to February 2020, he was the global head of healthcare investing at New Enterprise
extensive experience building, leading and financing biopharmaceutical companies will add significant value to Novavax' board,
especially now as we laser-focus on contributing to some of the world's most daunting healthcare challenges," said
Stanley C. Erck, President and Chief Executive Officer of Novavax. "We welcome his insights and guidance as we continue rapid
clinical development of NVX-CoV2373, our COVID-19 vaccine candidate, prepare for NanoFlu regulatory submission, and explore
paths forward for ResVax against RSV+ (respiratory syncytial virus)."
to join the Board of Directors of Novavax and look forward to working with my fellow Board members to help advance the company's
critical mission to prevent serious infectious disease, which is more important today than ever," said Mr. Mott. "I
look forward to supporting the Novavax team as it continues clinical development of its vaccine candidates and prepares for potential
Mr. Mott is currently
a private investor through Mott Family Capital. Mr. Mott has recently acquired nearly 65,000 shares of Novavax common stock prior
to his appointment. He serves as Chairman of the Board for Adaptimmune, Ardelyx, Epizyme, Imara and Mersana. From 2008 to 2020,
Mr. Mott was general partner at NEA, one of the world's largest venture capital firms, which invests in companies across
all stages in healthcare and technology. He led the NEA healthcare investing practice, with a primary focus on biopharmaceuticals.
Mr. Mott served as President and Chief Executive Officer, Vice Chairman of MedImmune from 2000 through 2008, during which he led
the sale of the company to AstraZeneca in June 2007 for $15.6 billion. He joined Medimmune in 1992 and served in various senior
roles during his tenure, including Chief Operating Officer and Chief Financial Officer. Earlier in his career he was a Vice
President in healthcare investment banking at Smith Barney, Harris Upham & Co., Inc. During the course of his career, Mr. Mott
has been involved in over $40 billion in corporate acquisitions, fundraising, partnerships and other capital formation. He
has been involved in more than 35 initial public offerings or corporate acquisitions, in bringing over a dozen new drugs through
development to commercialization and has served on 25 corporate boards. Mr. Mott holds a Bachelor of Arts degree from Dartmouth
serve on the Compensation Committee of Novavax' Board.
Novavax, Inc. (Nasdaq:NVAX) is a late-stage
biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative
vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against
SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu , its quadrivalent
influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine
candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response
and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant
technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles
in order to address urgent global health needs.
For more information, visit www.novavax.com
and connect with us on Twitter and LinkedIn.
herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements
regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these
forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially
from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk
Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and
Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel
vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.
You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties.
The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation
to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Silvia Taylor and Erika Trahan
Brandzone/KOGS Communication